Tarsier Pharma, a clinical-stage Israeli biotech developing steroid-free eye drop therapies for uveitis and related ocular conditions, filed for a modest NYSE American IPO targeting roughly $50 million in proceeds at an $8–10 per share range, implying a ~$294–299 million post-money valuation. However, the planned July 2026 pricing and listing did not occur amid the narrow window for small-cap biotechs, limited investor appetite for pre-revenue Phase 3 assets, and broader equity market conditions. With the August 31 cutoff approaching, traders have assigned a 99.4% implied probability to no IPO before September 2026, reflecting the absence of updated filings, roadshow activity, or revised terms. A sharp rebound in biotech sentiment, positive Tarsier-04 trial initiation data, or renewed underwriter support could still reopen the window in the final days.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · ActualizadoNo salida a bolsa antes de septiembre de 2026 99.4%
$250M-$300M 1.3%
$350M-$400M 1.3%
$400M-$450M 1.3%
$15,682 Vol.
$15,682 Vol.
9 jul 2026
<$250M
1%
$250M-$300M
1%
$300M-$350M
<1%
$350M-$400M
1%
$400M-$450M
1%
>$450M
<1%
No salida a bolsa antes de septiembre de 2026
99%
No salida a bolsa antes de septiembre de 2026 99.4%
$250M-$300M 1.3%
$350M-$400M 1.3%
$400M-$450M 1.3%
$15,682 Vol.
$15,682 Vol.
9 jul 2026
<$250M
$957 Vol.
1%
$250M-$300M
$979 Vol.
1%
$300M-$350M
$761 Vol.
<1%
$350M-$400M
$561 Vol.
1%
$400M-$450M
$349 Vol.
1%
>$450M
$680 Vol.
<1%
No salida a bolsa antes de septiembre de 2026
$11,395 Vol.
99%
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma, a clinical-stage Israeli biotech developing steroid-free eye drop therapies for uveitis and related ocular conditions, filed for a modest NYSE American IPO targeting roughly $50 million in proceeds at an $8–10 per share range, implying a ~$294–299 million post-money valuation. However, the planned July 2026 pricing and listing did not occur amid the narrow window for small-cap biotechs, limited investor appetite for pre-revenue Phase 3 assets, and broader equity market conditions. With the August 31 cutoff approaching, traders have assigned a 99.4% implied probability to no IPO before September 2026, reflecting the absence of updated filings, roadshow activity, or revised terms. A sharp rebound in biotech sentiment, positive Tarsier-04 trial initiation data, or renewed underwriter support could still reopen the window in the final days.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Mercado abierto: Jul 7, 2026, 9:12 AM ET
Volumen
$15,682Fecha de finalización
9 jul 2026Mercado abierto
Jul 7, 2026, 9:12 AM ETResolver
0x69c47De9D...This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma, a clinical-stage Israeli biotech developing steroid-free eye drop therapies for uveitis and related ocular conditions, filed for a modest NYSE American IPO targeting roughly $50 million in proceeds at an $8–10 per share range, implying a ~$294–299 million post-money valuation. However, the planned July 2026 pricing and listing did not occur amid the narrow window for small-cap biotechs, limited investor appetite for pre-revenue Phase 3 assets, and broader equity market conditions. With the August 31 cutoff approaching, traders have assigned a 99.4% implied probability to no IPO before September 2026, reflecting the absence of updated filings, roadshow activity, or revised terms. A sharp rebound in biotech sentiment, positive Tarsier-04 trial initiation data, or renewed underwriter support could still reopen the window in the final days.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volumen
$15,682Fecha de finalización
9 jul 2026Mercado abierto
Jul 7, 2026, 9:12 AM ETResolver
0x69c47De9D...Tarsier Pharma, a clinical-stage Israeli biotech developing steroid-free eye drop therapies for uveitis and related ocular conditions, filed for a modest NYSE American IPO targeting roughly $50 million in proceeds at an $8–10 per share range, implying a ~$294–299 million post-money valuation. However, the planned July 2026 pricing and listing did not occur amid the narrow window for small-cap biotechs, limited investor appetite for pre-revenue Phase 3 assets, and broader equity market conditions. With the August 31 cutoff approaching, traders have assigned a 99.4% implied probability to no IPO before September 2026, reflecting the absence of updated filings, roadshow activity, or revised terms. A sharp rebound in biotech sentiment, positive Tarsier-04 trial initiation data, or renewed underwriter support could still reopen the window in the final days.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · ActualizadoRelacionado
¿Tendrá Lyntris una capitalización de mercado inferior a $2 mil millones al cierre del mercado en el día de su OPI?
92%
Sí
¿CopperTech Metals no saldrá a bolsa antes de septiembre de 2026?
99%
Sí
¿La capitalización de mercado de Discord estará entre $8B y $11B al cierre del mercado en el día de su OPI antes del 31 de diciembre de 2027?
25%
Sí
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes